ANXA1 and COVID-19: The logistic regression analysis showed that increasing AnxA1 (per ten units) was associated with an increased risk of thrombotic events in patients with COVID-19 (OR 1.064 (95% CI 1.003–1.129); p = 0.040), as did the multivariable analysis (OR 1.067 (95% CI 1.002–1.135); p = 0.042) after adjustment for sex (Table 2, Table S4).